An anonymous director reports

ROADMAN UPDATES ON ACQUISITION TARGET CLOV BIOPHARMA CORP.

Roadman Investments Corp.'s pending acquisition target, CLOV Biopharma Corp. (CBP), is continuing to advance its business plan in an effort to expedite its mandate of advancing the research and potential commercial viability of cedar leaf oil vapour specifically in the pharmaceutical, health care and biotechnology sectors. CBP's corporate mission is to conduct further research and development of cedar leaf oil vapour (CLOV) for the purposes of preventing the spread of coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial viruses. Previously published manuscripts authored by CBP's medical scientific adviser, Dr. James Hudson, a foremost Canadian virologist, have concluded that, in a laboratory setting, CLOV was effective in killing (inactivating) several human respiratory viruses, including Influenza virus, Rhinovirus and Adenovirus, as well as Herpes simplex virus. It was also shown that short-term exposure to CLOV had no adverse effect on cultured lung epithelial cells, thus confirming it is not cytotoxic. Furthermore, it was shown that CLOV also partly reversed the pro-inflammatory effect caused by Rhinovirus infection, which means that it acts as a multifunctional therapeutic agent.

CBP has identified a number of diffusers that it believes will be functional with cedar leaf oil and cedar leaf oil vapour and, as such, it intends to begin testing these diffusers immediately. Portable, hand-held and stationary diffusers have been identified as functional candidates for further testing. Previously, both anecdotal and laboratory confirmed tests obtained through in-field studies in a commercial domicile setting have shown that both mould and bacteria levels had dropped significantly when diffused CLOV was present in the air. Additionally, a 2010 research project by Dr. Hudson showed that cedar leaf oil vapour killed the top medically important antimicrobial resistant organisms that are responsible for hospital-acquired infections. It is the intent of CLOV Biopharma to further validate these findings and phenomenon and, if warranted, enact a strategy to roll out and commercialize a product suite for personal and household use.

Roadman has executed a definitive agreement pursuant to which Roadman has acquired, subject to TSX Venture Exchange approval, all of the issued and outstanding shares of CLOV Biopharma in exchange for 13 million common shares of the company.

About Roadman Investments Corp.

Roadman Investments is a Canadian venture capital and advisory firm that strives to actively drive innovation and accelerate growth within its portfolio holdings in order to realize alpha returns for its shareholders. Roadman invests capital into companies that offer breakthrough products, devices, treatments and health supplements.

We seek Safe Harbor.